P2Y11 Antagonist B7508: Advanced Insights for Autoimmune and Neuroinflammation Research

Introduction

The P2Y11 antagonist (SKU: B7508) stands at the forefront of GPCR signaling pathway research, offering scientists a powerful tool to interrogate the intricacies of purinergic receptor-mediated signaling. As a sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate compound, its distinctive structure and high specificity have enabled breakthroughs in understanding cell signaling, immunology, and inflammation. While previous literature has focused primarily on cancer invasiveness and translational workflows, this article provides a differentiated perspective by delving into the underexplored roles of the P2Y11 antagonist in autoimmune disease research and neuroinflammation, contextualized within the broader landscape of GPCR antagonism and purinergic signaling.

Biochemical Profile and Handling of P2Y11 Antagonist B7508

P2Y11 antagonist B7508 is supplied as a beige solid with a molecular weight of 986.84 and a chemical formula of C37H26N4Na4O15S4. Its notable solubility in water at concentrations below 19.74 mg/ml makes it adaptable to a variety of in vitro assays. To preserve its stability, the reagent should be stored at -20°C and is shipped under blue ice conditions to maintain its integrity during transit. Researchers should note that this compound is intended strictly for scientific research and not for diagnostic or medical use; solutions should be prepared fresh and utilized promptly to prevent degradation.

The P2Y11 Receptor: A Nexus in GPCR and Purinergic Signaling

The P2Y11 receptor is a member of the G protein-coupled receptor (GPCR) family, playing a crucial role in the regulation of immune responses and inflammatory processes. Unlike other P2Y receptors, P2Y11 uniquely couples to both G_s and G_q proteins, leading to dual activation of adenylate cyclase and phospholipase C pathways. This duality positions P2Y11 as a key modulator of intracellular calcium and cyclic AMP (cAMP), integrating signals that orchestrate cell migration, cytokine release, and inflammation pathway modulation.

Mechanism of Action: P2Y11 Antagonist as a Cell Signaling Inhibitor

The B7508 P2Y11 antagonist functions by selectively inhibiting the P2Y11 receptor, thereby disrupting both cAMP and calcium-dependent pathways. This antagonism results in the attenuation of downstream signaling cascades associated with immune cell activation, chemotaxis, and inflammation. In autoimmune models, such inhibition offers the potential to temper aberrant immune responses, while in neuroinflammatory contexts, P2Y11 blockade may mitigate microglial activation and neuronal damage.

Expanding the Application Spectrum: Autoimmune Disease and Neuroinflammation

Autoimmune Disease Research

Emerging evidence suggests purinergic signaling, particularly via P2Y11, plays a pivotal role in the dysregulation seen in autoimmune disorders. By acting as a cell signaling inhibitor targeting the P2Y11 receptor, B7508 enables researchers to dissect the contribution of this pathway in diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. Selective antagonism allows for interrogation of immune cell migration, cytokine storm phenomena, and the interplay between innate and adaptive immunity.

Neuroinflammation Studies

P2Y11 has been implicated in neuroinflammatory processes, including microglial activation and astrocyte signaling. Studies utilizing the B7508 antagonist can help elucidate the receptor’s role in neurodegenerative disease models, such as Alzheimer’s and Parkinson’s, where excessive purinergic signaling exacerbates neuronal injury. By modulating the GPCR signaling pathway, B7508 offers a unique tool for mapping neuroimmune cross-talk and identifying novel therapeutic targets.

Case Study: Modulation of Breast Cancer Invasiveness via P2Y11 Antagonism

While this article is distinct in its focus on autoimmune and neuroinflammation research, it is instructive to consider the broader implications of P2Y11 antagonism in cancer biology. A seminal study by Liu et al. (Frontiers in Endocrinology, 2021) revealed that upregulation of quinolinate phosphoribosyltransferase (QPRT) in invasive breast cancer augments myosin light chain phosphorylation, driving tumor invasiveness. Crucially, the application of a P2Y11 antagonist (NF340, equivalent to B7508) reversed QPRT-induced migratory and invasive behavior in breast cancer cells. This mechanism, mediated via the purinergic signaling axis and corroborated by the use of Rho/ROCK/PLC pathway inhibitors, underscores the versatility of P2Y11 antagonists in modulating diverse pathological processes, from cancer to autoimmunity and neuroinflammation.

Comparative Analysis: B7508 Versus Alternative Cell Signaling Inhibitors

Compared to broader spectrum GPCR antagonists or purinergic inhibitors, B7508 offers unparalleled specificity for the P2Y11 receptor. Alternative approaches, such as genetic knockdown or use of less selective inhibitors, often result in off-target effects that can confound the interpretation of complex signaling networks. The unique chemical structure of sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate ensures high selectivity and reproducibility in experimental outcomes.

While recent articles such as "P2Y11 Antagonist in GPCR Signaling: Advanced Research App…" provide valuable workflow optimization tips and troubleshooting strategies for molecular investigations, the present article distinguishes itself by mapping the translational leap from these cellular models to complex disease systems, particularly in autoimmunity and neuroinflammation. This deeper application focus fills a key content gap not addressed in experimental workflow guides.

Integration with Systems Biology and Translational Research

Building upon the systems biology perspective outlined in "P2Y11 Antagonist B7508: A Systems Biology Perspective on…", this article advances the discussion by connecting cellular and molecular insights to disease-relevant models. Rather than confining the analysis to pathway diagrams or isolated cell lines, we explore the compound’s role in modulating entire immune networks and neuroimmune circuits. This approach not only strengthens the translational relevance of the P2Y11 antagonist but also positions it as a foundation for multi-modal therapeutic discovery.

Experimental Best Practices and Considerations

For optimal results, researchers should adhere to these best practices when working with B7508:

• Prepare solutions fresh to avoid degradation; long-term storage of diluted solutions is not recommended.
• Ensure storage at -20°C to preserve compound stability.
• Implement appropriate controls for specificity, given the high selectivity of B7508 for the P2Y11 receptor.
• Integrate complementary readouts (e.g., phospho-protein analysis, cytokine profiling) to fully capture pathway modulation.

These guidelines complement, but differ in focus from, the troubleshooting strategies highlighted in "P2Y11 Antagonist B7508: Next-Gen Insights for Targeting G…", which emphasizes mechanistic depth in cancer and inflammation. Here, the emphasis is on expanding the practical toolkit for immunology and neuroinflammation researchers.

Accessing the P2Y11 Antagonist for Research

Researchers interested in leveraging this advanced cell signaling inhibitor targeting the P2Y11 receptor can obtain detailed specifications, handling guidelines, and ordering information from APExBIO’s official product page: P2Y11 antagonist B7508. The reagent’s rigorous quality standards and comprehensive documentation support its integration into cutting-edge research workflows.

Conclusion and Future Outlook

The P2Y11 antagonist B7508 is more than a precision tool for dissecting GPCR signaling; it is a gateway to understanding and modulating complex disease mechanisms in autoimmunity and neuroinflammation. By providing high selectivity and robust, reproducible inhibition of the P2Y11 receptor, B7508 empowers researchers to chart new territories in the study of immune regulation, neuroimmune interactions, and inflammation pathway modulation. As illustrated by recent translational findings (Liu et al., 2021), such targeted approaches are poised to inform the next generation of therapeutic strategies. For investigators seeking to move beyond established paradigms in GPCR and P2Y receptor signaling, APExBIO’s P2Y11 antagonist B7508 represents an indispensable asset for future discovery.